These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25592412)

  • 1. An explorative study regarding the effect of l-deprenyl on cognitive and functional recovery in patients after stroke.
    Bartolo M; Zucchella C; Capone A; Sandrini G; Pierelli F
    J Neurol Sci; 2015 Feb; 349(1-2):117-23. PubMed ID: 25592412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline treatment facilitates recovery after stroke.
    Sivenius J; Sarasoja T; Aaltonen H; Heinonen E; Kilkku O; Reinikainen K
    Neurorehabil Neural Repair; 2001; 15(3):183-90. PubMed ID: 11944739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
    Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG
    Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness and tolerability of selegiline in the treatment of pathological cerebral involutions].
    Bettini R; Gorini M
    Clin Ter; 2002; 153(6):377-80. PubMed ID: 12645393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders.
    Neurology; 1998 Mar; 50(3):645-51. PubMed ID: 9521250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trial of L-deprenyl for the treatment of neuroleptic-induced parkinsonism.
    Rapoport A; Stein D; Schwartz M; Levin J; Stier S; Elizur A; Rabey JM
    J Neural Transm (Vienna); 1999; 106(9-10):911-8. PubMed ID: 10599872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study.
    Jungerman T; Rabinowitz D; Klein E
    J Clin Psychopharmacol; 1999 Dec; 19(6):522-5. PubMed ID: 10587287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease.
    Tolbert SR; Fuller MA
    Ann Pharmacother; 1996 Oct; 30(10):1122-9. PubMed ID: 8998375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postinjury administration of L-deprenyl improves cognitive function and enhances neuroplasticity after traumatic brain injury.
    Zhu J; Hamm RJ; Reeves TM; Povlishock JT; Phillips LL
    Exp Neurol; 2000 Nov; 166(1):136-52. PubMed ID: 11031090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive effects of L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Weingartner H; Murphy DL; Welkowitz JA; Thompson K; Cohen RM
    Psychopharmacology (Berl); 1987; 91(4):489-95. PubMed ID: 3108930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety.
    Ernst M; Liebenauer LL; Jons PH; Tebeka D; Cohen RM; Zametkin AJ
    Psychopharmacol Bull; 1996; 32(3):327-34. PubMed ID: 8961775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease.
    Lawlor BA; Aisen PS; Green C; Fine E; Schmeïdler J
    Int J Geriatr Psychiatry; 1997 Mar; 12(3):319-22. PubMed ID: 9152715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.